IOCB Tech

IOCBTech is a technology transfer office of IOCB Prague. It focuses on transferring the top basic research, such as medicinal chemistry, to human use.

[IOCB Tech @IOCBTech]

@julieinprague from IOCB Tech will be at #BIOEurope 2026 in Cologne, 9–11 Nov.

Open to meetings and conversations on tech transfer, partnering and life sciences.

Meet Julie at the https://t.co/8B8mt6i5yz booth or connect via the BIO-Europe partnering platform.

[IOCB Tech @IOCBTech]

What does it take to build stronger biotech startups in Europe?

A recent visit by the @EIF_EU to @IOCBPrague opened a discussion on capital, talent, and the conditions needed to help young biotech companies grow.

https://t.co/XIKO5bAeJP

#Biotech #TechTransfer #VentureCapital

[IOCB Tech @IOCBTech]

Last week, we welcomed a @BIOAsia_Taiwan delegation to IOCB Prague.

Together with https://t.co/8B8mt6i5yz, we introduced the Czech biotech ecosystem, @IOCBPrague, and the innovation network around it.

#Biotech #TechTransfer #Taiwan

[IOCB Tech @IOCBTech]

A Polish visit, a shared interest in innovation, and plenty to build on.

On Monday at PharmTheon, we welcomed colleagues from @IMol_Institute and the @IIMCB_Poland to discuss future collaboration and present the @IOCBPrague innovation ecosystem.

#Biotech #TechTransfer

[IOCB Tech @IOCBTech]

A game with a scientific twist? Prague has one.

Mission Retrovirus is a new outdoor game in Dejvice inspired by Czech antiviral research and the legacy of Antonín Holý. Play outdoors or online. From September, the game will also be available in English.

https://t.co/kuJ7gVmPii

[IOCB Tech @IOCBTech]

What biological question would you ask if feasibility were not the first constraint?

That is the idea behind the new #DreamBiologyAward by IOCB Prague — an international competition for bold life science visions. Apply by 31 July 2026.

More info: https://t.co/ibUUpNZArA

[IOCB Tech @IOCBTech]

Background in life sciences and thinking about the business side of biotech?

Applications for the 2nd edition of the https://t.co/6UpjtUhPSJ Executive Academy are open until 31 July.

Learn more and apply here: https://t.co/y2PbHQeOVK

#LifeSciences #Biotech #ExecutiveAcademy

[IOCB Tech @IOCBTech]

Czech biotech stands on stronger foundations than many still assume. Nearly 430 entities, € 4bn in annual revenue, and growing investor attention all point in the right direction.

The next challenge is clear: turning strong science into investable, scalable projects.

#Czechia

[IOCB Tech @IOCBTech]

Boston is not just a location. It is a concentration of capital, experience, and decision-making.

For Central European projects, that means a very different operating environment. Through @IOCBBoston, we are not starting from zero — we are already part of that ecosystem.

[IOCB Tech @IOCBTech]

Join us at Bio€quity Europe 2026 for the Regional Host Panel: How to Bring Great Science to Market – The CEE Case.

@julieinprague will join the discussion, moderated by @valkova_zuzana.

📅 5 May
🕓 4:00 pm
#BioEquity #Biotech #TechTransfer #CEE

[IOCB Tech @IOCBTech]

#BioVaria is in full swing, and we’re glad to be part of it in Munich.

Great to be here with colleagues from i&i Prague, PharmTheon and other partners — with support from Lukáš Opatrný (Czech General Consulate) and https://t.co/6UpjtUhPSJ helping strengthen the Czech presence.

[IOCB Tech @IOCBTech]

BioVaria 2026 starts in Munich on Monday.

Over two days, the event will bring together investors, innovators and tech transfer professionals from across Europe. IOCB Tech is proud to be a power partner and to contribute with five presentations.

#BioVaria #LifeSciences #Biotech

[IOCB Tech @IOCBTech]

Most projects do not fail because the science is weak. They fail in the space between discovery and use — where relevance, risk, and real-world fit become the real test. That middle layer may be less visible, but it is where projects become viable.

#TechTransfer #Innovation

[IOCB Tech @IOCBTech]

Some progress in life sciences comes from improving the methods science already relies on.

Great to see LAM-X develop VerdiBlot and advance work on nanomaterials — a strong example of technical innovation in the layer that underpins experimental biology.

#LifeSciences #Biotech

[IOCB Tech @IOCBTech]

Bio€quity Europe is just around the corner — and this year, Prague will host it.

From 4–6 May 2026, the event will bring investors, biotech companies, and tech transfer professionals together in Prague. For IOCB Tech, it is a valuable chance to strengthen links between research, investment, and application.

#BioEquity #Biotech #TechTransfer

[IOCB Tech @IOCBTech]

For more information, visit: https://t.co/bw67ll0Eg6

[IOCB Tech @IOCBTech]

Some of the biggest advances in life sciences are not therapies, but tools.

Western blot, ELISA, PCR — methods that shape what scientists are able to see. Great to see LAM-X building on that logic with VerdiBlot, a new bioanalytical method for more reliable protein analysis.

Congrats.

#Bioanalysis #DrugDiscovery #LifeSciences #Biotech

[IOCB Tech @IOCBTech]

Czechia does not underperform in research investment. Around 2% of GDP goes into R&D, and the scientific base is strong.

The challenge comes later: turning research into companies, products, and real market presence.

That is where IOCB Tech works — helping strong projects move from discovery toward application.

#TechTransfer #Innovation #LifeSciences

[IOCB Tech @IOCBTech]

🇵🇹 We’re delighted to be at BIO-Europe Spring in beautiful Lisbon, Portugal, alongside our colleagues from https://t.co/ismxumerIK
Come and meet us at BOOTH 73. 🤝🧬

For the next few days, this city is bringing together over 3,700 professional visitors and more than 2,000 exhibitors — and we’re very glad to be part of it.

#BIOEuropeSpring #Lisbon #Biotech #LifeSciences #Networking #Innovation

[IOCB Tech @IOCBTech]

https://t.co/4S53J0mGj3

[IOCB Tech @IOCBTech]

🎧 Today’s question: Which biotech podcasts are actually worth listening to?

Podcast listening is growing fast in the Czech Republic — weekly reach rose from 36% in 2023 to 44% in 2025. But does the same already apply to biotech?

One tip from us: Martin Kovalčík from #i&i Prague interviewed Jan Berka, who helps develop the portfolio of i&i Prague projects, in a new episode of #ChemagazinTalks.

👉 Link in comments
📷 Photo: i&i Prague

#Biotech #Podcast #TechTransfer